Could This Humira Biosimilar Be a Winner for Amgen?
At the end of January, Amgen (NASDAQ: AMGN) celebrated the U.S. launch of its biosimilar Amjevita to AbbVie's (NYSE: ABBV) star immunology drug called Humira. Amgen's Amjevita received approval from the U.S. Food and Drug Administration (FDA) as a biosimilar in 2016.